Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe of Odyssey Capital Advisors said Oracle Corporation ORCL is going to report a strong quarter and recommended staying long on the stock.

Oracle is scheduled to release quarterly earnings after the closing bell today. Analysts expect the company to post quarterly earnings at $1.48 per share on revenue of $14.11 billion.

Stephen Weiss of Short Hills Capital Partners named Vertiv Holdings Co VRT as his final trade.

On Oct. 23, Vertiv reported third-quarter results. Net sales rose 19% year-over-year to $2.074 billion, beating the consensus of $1.977 billion. Organic orders (excluding foreign exchange) rose 17%. Adjusted operating profit surged 41% to $417 million, with the margin expanding 310 basis points to 20.1%, driven by higher volumes and favorable commercial execution.

Don't forget to check out our premarket coverage here

Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said GSK plc GSK has a 4.5% dividend yield.

On Nov. 19, GSK released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo.

Price Action:

• Oracle shares gained by 2.9% to close at $191.69 on Friday.
• Vertiv shares fell by 0.5% to settle at $133.85 during Friday's session.
• GSK shares gained by 0.1% to close at $34.57 on Friday.

Check This Out:

• How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings

Image: Shutterstock